nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—kidney cancer	0.414	1	CbGaD
Fidaxomicin—ABCB1—Temsirolimus—kidney cancer	0.101	0.225	CbGbCtD
Fidaxomicin—ABCB1—Pazopanib—kidney cancer	0.0533	0.118	CbGbCtD
Fidaxomicin—ABCB1—Dactinomycin—kidney cancer	0.0487	0.108	CbGbCtD
Fidaxomicin—ABCB1—Gemcitabine—kidney cancer	0.0385	0.0856	CbGbCtD
Fidaxomicin—ABCB1—Erlotinib—kidney cancer	0.038	0.0845	CbGbCtD
Fidaxomicin—ABCB1—Paclitaxel—kidney cancer	0.0348	0.0773	CbGbCtD
Fidaxomicin—ABCB1—Sorafenib—kidney cancer	0.0309	0.0687	CbGbCtD
Fidaxomicin—ABCB1—Vinblastine—kidney cancer	0.0305	0.0678	CbGbCtD
Fidaxomicin—ABCB1—Vincristine—kidney cancer	0.03	0.0667	CbGbCtD
Fidaxomicin—ABCB1—Sunitinib—kidney cancer	0.025	0.0557	CbGbCtD
Fidaxomicin—ABCB1—Doxorubicin—kidney cancer	0.0188	0.0417	CbGbCtD
Fidaxomicin—Angioedema—Everolimus—kidney cancer	0.000503	0.00371	CcSEcCtD
Fidaxomicin—Dyspepsia—Pazopanib—kidney cancer	0.0005	0.00369	CcSEcCtD
Fidaxomicin—Immune system disorder—Sorafenib—kidney cancer	0.000495	0.00365	CcSEcCtD
Fidaxomicin—Neutropenia—Gemcitabine—kidney cancer	0.000495	0.00365	CcSEcCtD
Fidaxomicin—Decreased appetite—Pazopanib—kidney cancer	0.000494	0.00365	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Temsirolimus—kidney cancer	0.000493	0.00364	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000491	0.00362	CcSEcCtD
Fidaxomicin—Malnutrition—Sorafenib—kidney cancer	0.000477	0.00352	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Gemcitabine—kidney cancer	0.000477	0.00352	CcSEcCtD
Fidaxomicin—Abdominal pain—Temsirolimus—kidney cancer	0.000477	0.00352	CcSEcCtD
Fidaxomicin—Immune system disorder—Sunitinib—kidney cancer	0.000477	0.00352	CcSEcCtD
Fidaxomicin—Dysgeusia—Sorafenib—kidney cancer	0.000468	0.00345	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000465	0.00343	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Pazopanib—kidney cancer	0.000465	0.00343	CcSEcCtD
Fidaxomicin—Malnutrition—Sunitinib—kidney cancer	0.000459	0.00339	CcSEcCtD
Fidaxomicin—Dry mouth—Everolimus—kidney cancer	0.000458	0.00338	CcSEcCtD
Fidaxomicin—Flatulence—Sunitinib—kidney cancer	0.000453	0.00334	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Paclitaxel—kidney cancer	0.000452	0.00333	CcSEcCtD
Fidaxomicin—Dysgeusia—Sunitinib—kidney cancer	0.00045	0.00332	CcSEcCtD
Fidaxomicin—Abdominal pain—Pazopanib—kidney cancer	0.000449	0.00331	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000449	0.00331	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Gemcitabine—kidney cancer	0.000446	0.00329	CcSEcCtD
Fidaxomicin—Abdominal distension—Paclitaxel—kidney cancer	0.000446	0.00329	CcSEcCtD
Fidaxomicin—Hypersensitivity—Temsirolimus—kidney cancer	0.000445	0.00328	CcSEcCtD
Fidaxomicin—Dysphagia—Paclitaxel—kidney cancer	0.000443	0.00327	CcSEcCtD
Fidaxomicin—Anaemia—Sorafenib—kidney cancer	0.000441	0.00325	CcSEcCtD
Fidaxomicin—Nervous system disorder—Everolimus—kidney cancer	0.00044	0.00325	CcSEcCtD
Fidaxomicin—Angioedema—Sorafenib—kidney cancer	0.000436	0.00322	CcSEcCtD
Fidaxomicin—Skin disorder—Everolimus—kidney cancer	0.000436	0.00322	CcSEcCtD
Fidaxomicin—Pruritus—Temsirolimus—kidney cancer	0.000427	0.00315	CcSEcCtD
Fidaxomicin—Nervous system disorder—Erlotinib—kidney cancer	0.000425	0.00313	CcSEcCtD
Fidaxomicin—Anaemia—Sunitinib—kidney cancer	0.000425	0.00313	CcSEcCtD
Fidaxomicin—Skin disorder—Erlotinib—kidney cancer	0.000421	0.0031	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Capecitabine—kidney cancer	0.000421	0.0031	CcSEcCtD
Fidaxomicin—Angioedema—Sunitinib—kidney cancer	0.00042	0.0031	CcSEcCtD
Fidaxomicin—Neutropenia—Paclitaxel—kidney cancer	0.000414	0.00305	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000404	0.00298	CcSEcCtD
Fidaxomicin—Pruritus—Pazopanib—kidney cancer	0.000402	0.00297	CcSEcCtD
Fidaxomicin—Anaemia—Dactinomycin—kidney cancer	0.000402	0.00296	CcSEcCtD
Fidaxomicin—Dyspnoea—Everolimus—kidney cancer	0.0004	0.00295	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Paclitaxel—kidney cancer	0.0004	0.00295	CcSEcCtD
Fidaxomicin—Dizziness—Temsirolimus—kidney cancer	0.000399	0.00294	CcSEcCtD
Fidaxomicin—Dry mouth—Sorafenib—kidney cancer	0.000398	0.00293	CcSEcCtD
Fidaxomicin—Dyspepsia—Everolimus—kidney cancer	0.000395	0.00291	CcSEcCtD
Fidaxomicin—Decreased appetite—Vinblastine—kidney cancer	0.000392	0.00289	CcSEcCtD
Fidaxomicin—Decreased appetite—Everolimus—kidney cancer	0.00039	0.00288	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000388	0.00286	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Everolimus—kidney cancer	0.000388	0.00286	CcSEcCtD
Fidaxomicin—Dyspnoea—Erlotinib—kidney cancer	0.000386	0.00285	CcSEcCtD
Fidaxomicin—Constipation—Vinblastine—kidney cancer	0.000385	0.00284	CcSEcCtD
Fidaxomicin—Constipation—Everolimus—kidney cancer	0.000384	0.00283	CcSEcCtD
Fidaxomicin—Vomiting—Temsirolimus—kidney cancer	0.000384	0.00283	CcSEcCtD
Fidaxomicin—Dry mouth—Sunitinib—kidney cancer	0.000383	0.00282	CcSEcCtD
Fidaxomicin—Immune system disorder—Gemcitabine—kidney cancer	0.000383	0.00282	CcSEcCtD
Fidaxomicin—Nervous system disorder—Sorafenib—kidney cancer	0.000382	0.00282	CcSEcCtD
Fidaxomicin—Dyspepsia—Erlotinib—kidney cancer	0.000381	0.00281	CcSEcCtD
Fidaxomicin—Rash—Temsirolimus—kidney cancer	0.000381	0.00281	CcSEcCtD
Fidaxomicin—Dermatitis—Temsirolimus—kidney cancer	0.00038	0.0028	CcSEcCtD
Fidaxomicin—Skin disorder—Sorafenib—kidney cancer	0.000379	0.00279	CcSEcCtD
Fidaxomicin—Headache—Temsirolimus—kidney cancer	0.000378	0.00279	CcSEcCtD
Fidaxomicin—Decreased appetite—Erlotinib—kidney cancer	0.000377	0.00278	CcSEcCtD
Fidaxomicin—Dizziness—Pazopanib—kidney cancer	0.000376	0.00277	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000374	0.00276	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Paclitaxel—kidney cancer	0.000374	0.00275	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.000371	0.00274	CcSEcCtD
Fidaxomicin—Constipation—Erlotinib—kidney cancer	0.00037	0.00273	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vinblastine—kidney cancer	0.000369	0.00272	CcSEcCtD
Fidaxomicin—Nervous system disorder—Sunitinib—kidney cancer	0.000368	0.00271	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Everolimus—kidney cancer	0.000367	0.00271	CcSEcCtD
Fidaxomicin—Abdominal distension—Capecitabine—kidney cancer	0.000366	0.0027	CcSEcCtD
Fidaxomicin—Skin disorder—Sunitinib—kidney cancer	0.000364	0.00269	CcSEcCtD
Fidaxomicin—Dysphagia—Capecitabine—kidney cancer	0.000364	0.00268	CcSEcCtD
Fidaxomicin—Vomiting—Pazopanib—kidney cancer	0.000361	0.00267	CcSEcCtD
Fidaxomicin—Anaemia—Vincristine—kidney cancer	0.000359	0.00265	CcSEcCtD
Fidaxomicin—Rash—Pazopanib—kidney cancer	0.000358	0.00264	CcSEcCtD
Fidaxomicin—Nausea—Temsirolimus—kidney cancer	0.000358	0.00264	CcSEcCtD
Fidaxomicin—Dermatitis—Pazopanib—kidney cancer	0.000358	0.00264	CcSEcCtD
Fidaxomicin—Abdominal pain—Vinblastine—kidney cancer	0.000356	0.00263	CcSEcCtD
Fidaxomicin—Headache—Pazopanib—kidney cancer	0.000356	0.00263	CcSEcCtD
Fidaxomicin—Abdominal pain—Everolimus—kidney cancer	0.000355	0.00262	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Erlotinib—kidney cancer	0.000354	0.00261	CcSEcCtD
Fidaxomicin—Dyspnoea—Sorafenib—kidney cancer	0.000347	0.00256	CcSEcCtD
Fidaxomicin—Dyspepsia—Sorafenib—kidney cancer	0.000343	0.00253	CcSEcCtD
Fidaxomicin—Abdominal pain—Erlotinib—kidney cancer	0.000342	0.00253	CcSEcCtD
Fidaxomicin—Anaemia—Gemcitabine—kidney cancer	0.000341	0.00251	CcSEcCtD
Fidaxomicin—Neutropenia—Capecitabine—kidney cancer	0.00034	0.00251	CcSEcCtD
Fidaxomicin—Decreased appetite—Sorafenib—kidney cancer	0.000339	0.0025	CcSEcCtD
Fidaxomicin—Nausea—Pazopanib—kidney cancer	0.000338	0.00249	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000336	0.00248	CcSEcCtD
Fidaxomicin—Dyspnoea—Sunitinib—kidney cancer	0.000334	0.00247	CcSEcCtD
Fidaxomicin—Constipation—Sorafenib—kidney cancer	0.000333	0.00246	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vinblastine—kidney cancer	0.000332	0.00245	CcSEcCtD
Fidaxomicin—Hypersensitivity—Everolimus—kidney cancer	0.000331	0.00244	CcSEcCtD
Fidaxomicin—Dyspepsia—Sunitinib—kidney cancer	0.00033	0.00243	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Capecitabine—kidney cancer	0.000328	0.00242	CcSEcCtD
Fidaxomicin—Decreased appetite—Sunitinib—kidney cancer	0.000326	0.0024	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000324	0.00239	CcSEcCtD
Fidaxomicin—Constipation—Sunitinib—kidney cancer	0.000321	0.00236	CcSEcCtD
Fidaxomicin—Immune system disorder—Paclitaxel—kidney cancer	0.00032	0.00236	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Sorafenib—kidney cancer	0.000319	0.00235	CcSEcCtD
Fidaxomicin—Pruritus—Everolimus—kidney cancer	0.000318	0.00234	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000312	0.0023	CcSEcCtD
Fidaxomicin—Nervous system disorder—Vincristine—kidney cancer	0.000311	0.00229	CcSEcCtD
Fidaxomicin—Malnutrition—Paclitaxel—kidney cancer	0.000309	0.00228	CcSEcCtD
Fidaxomicin—Decreased appetite—Dactinomycin—kidney cancer	0.000309	0.00228	CcSEcCtD
Fidaxomicin—Abdominal pain—Sorafenib—kidney cancer	0.000308	0.00227	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Sunitinib—kidney cancer	0.000307	0.00226	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Capecitabine—kidney cancer	0.000307	0.00226	CcSEcCtD
Fidaxomicin—Pruritus—Erlotinib—kidney cancer	0.000306	0.00226	CcSEcCtD
Fidaxomicin—Flatulence—Paclitaxel—kidney cancer	0.000304	0.00224	CcSEcCtD
Fidaxomicin—Dysgeusia—Paclitaxel—kidney cancer	0.000302	0.00223	CcSEcCtD
Fidaxomicin—Dizziness—Vinblastine—kidney cancer	0.000298	0.0022	CcSEcCtD
Fidaxomicin—Dizziness—Everolimus—kidney cancer	0.000297	0.00219	CcSEcCtD
Fidaxomicin—Abdominal pain—Sunitinib—kidney cancer	0.000296	0.00219	CcSEcCtD
Fidaxomicin—Nervous system disorder—Gemcitabine—kidney cancer	0.000295	0.00218	CcSEcCtD
Fidaxomicin—Skin disorder—Gemcitabine—kidney cancer	0.000292	0.00216	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00029	0.00214	CcSEcCtD
Fidaxomicin—Hypersensitivity—Sorafenib—kidney cancer	0.000287	0.00212	CcSEcCtD
Fidaxomicin—Vomiting—Vinblastine—kidney cancer	0.000287	0.00211	CcSEcCtD
Fidaxomicin—Dizziness—Erlotinib—kidney cancer	0.000286	0.00211	CcSEcCtD
Fidaxomicin—Vomiting—Everolimus—kidney cancer	0.000285	0.00211	CcSEcCtD
Fidaxomicin—Anaemia—Paclitaxel—kidney cancer	0.000285	0.0021	CcSEcCtD
Fidaxomicin—Rash—Everolimus—kidney cancer	0.000283	0.00209	CcSEcCtD
Fidaxomicin—Dermatitis—Everolimus—kidney cancer	0.000283	0.00209	CcSEcCtD
Fidaxomicin—Headache—Vinblastine—kidney cancer	0.000282	0.00208	CcSEcCtD
Fidaxomicin—Angioedema—Paclitaxel—kidney cancer	0.000282	0.00208	CcSEcCtD
Fidaxomicin—Headache—Everolimus—kidney cancer	0.000281	0.00207	CcSEcCtD
Fidaxomicin—Abdominal pain—Dactinomycin—kidney cancer	0.000281	0.00207	CcSEcCtD
Fidaxomicin—Hypersensitivity—Sunitinib—kidney cancer	0.000276	0.00204	CcSEcCtD
Fidaxomicin—Decreased appetite—Vincristine—kidney cancer	0.000276	0.00203	CcSEcCtD
Fidaxomicin—Pruritus—Sorafenib—kidney cancer	0.000276	0.00203	CcSEcCtD
Fidaxomicin—Vomiting—Erlotinib—kidney cancer	0.000275	0.00203	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000274	0.00202	CcSEcCtD
Fidaxomicin—Rash—Erlotinib—kidney cancer	0.000273	0.00201	CcSEcCtD
Fidaxomicin—Dermatitis—Erlotinib—kidney cancer	0.000273	0.00201	CcSEcCtD
Fidaxomicin—Headache—Erlotinib—kidney cancer	0.000271	0.002	CcSEcCtD
Fidaxomicin—Constipation—Vincristine—kidney cancer	0.000271	0.002	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000271	0.002	CcSEcCtD
Fidaxomicin—Dyspnoea—Gemcitabine—kidney cancer	0.000268	0.00198	CcSEcCtD
Fidaxomicin—Nausea—Vinblastine—kidney cancer	0.000268	0.00197	CcSEcCtD
Fidaxomicin—Nausea—Everolimus—kidney cancer	0.000267	0.00197	CcSEcCtD
Fidaxomicin—Pruritus—Sunitinib—kidney cancer	0.000265	0.00196	CcSEcCtD
Fidaxomicin—Immune system disorder—Capecitabine—kidney cancer	0.000263	0.00194	CcSEcCtD
Fidaxomicin—Decreased appetite—Gemcitabine—kidney cancer	0.000262	0.00193	CcSEcCtD
Fidaxomicin—Hypersensitivity—Dactinomycin—kidney cancer	0.000262	0.00193	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000261	0.00192	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00026	0.00192	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vincristine—kidney cancer	0.000259	0.00191	CcSEcCtD
Fidaxomicin—Dizziness—Sorafenib—kidney cancer	0.000258	0.0019	CcSEcCtD
Fidaxomicin—Constipation—Gemcitabine—kidney cancer	0.000257	0.0019	CcSEcCtD
Fidaxomicin—Nausea—Erlotinib—kidney cancer	0.000257	0.0019	CcSEcCtD
Fidaxomicin—Dry mouth—Paclitaxel—kidney cancer	0.000257	0.0019	CcSEcCtD
Fidaxomicin—Malnutrition—Capecitabine—kidney cancer	0.000253	0.00187	CcSEcCtD
Fidaxomicin—Abdominal pain—Vincristine—kidney cancer	0.000251	0.00185	CcSEcCtD
Fidaxomicin—Flatulence—Capecitabine—kidney cancer	0.00025	0.00184	CcSEcCtD
Fidaxomicin—Dysgeusia—Capecitabine—kidney cancer	0.000248	0.00183	CcSEcCtD
Fidaxomicin—Dizziness—Sunitinib—kidney cancer	0.000248	0.00183	CcSEcCtD
Fidaxomicin—Vomiting—Sorafenib—kidney cancer	0.000248	0.00183	CcSEcCtD
Fidaxomicin—Nervous system disorder—Paclitaxel—kidney cancer	0.000247	0.00182	CcSEcCtD
Fidaxomicin—Rash—Sorafenib—kidney cancer	0.000246	0.00181	CcSEcCtD
Fidaxomicin—Dermatitis—Sorafenib—kidney cancer	0.000245	0.00181	CcSEcCtD
Fidaxomicin—Skin disorder—Paclitaxel—kidney cancer	0.000245	0.0018	CcSEcCtD
Fidaxomicin—Headache—Sorafenib—kidney cancer	0.000244	0.0018	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000239	0.00176	CcSEcCtD
Fidaxomicin—Vomiting—Sunitinib—kidney cancer	0.000238	0.00176	CcSEcCtD
Fidaxomicin—Rash—Sunitinib—kidney cancer	0.000236	0.00174	CcSEcCtD
Fidaxomicin—Dermatitis—Sunitinib—kidney cancer	0.000236	0.00174	CcSEcCtD
Fidaxomicin—Abdominal distension—Doxorubicin—kidney cancer	0.000236	0.00174	CcSEcCtD
Fidaxomicin—Headache—Sunitinib—kidney cancer	0.000235	0.00173	CcSEcCtD
Fidaxomicin—Dysphagia—Doxorubicin—kidney cancer	0.000234	0.00173	CcSEcCtD
Fidaxomicin—Anaemia—Capecitabine—kidney cancer	0.000234	0.00173	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vincristine—kidney cancer	0.000234	0.00172	CcSEcCtD
Fidaxomicin—Nausea—Sorafenib—kidney cancer	0.000231	0.00171	CcSEcCtD
Fidaxomicin—Vomiting—Dactinomycin—kidney cancer	0.000226	0.00166	CcSEcCtD
Fidaxomicin—Dyspnoea—Paclitaxel—kidney cancer	0.000225	0.00166	CcSEcCtD
Fidaxomicin—Rash—Dactinomycin—kidney cancer	0.000224	0.00165	CcSEcCtD
Fidaxomicin—Nausea—Sunitinib—kidney cancer	0.000223	0.00164	CcSEcCtD
Fidaxomicin—Dyspepsia—Paclitaxel—kidney cancer	0.000222	0.00164	CcSEcCtD
Fidaxomicin—Neutropenia—Doxorubicin—kidney cancer	0.000219	0.00162	CcSEcCtD
Fidaxomicin—Decreased appetite—Paclitaxel—kidney cancer	0.000219	0.00161	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000217	0.0016	CcSEcCtD
Fidaxomicin—Constipation—Paclitaxel—kidney cancer	0.000215	0.00159	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000214	0.00158	CcSEcCtD
Fidaxomicin—Pruritus—Gemcitabine—kidney cancer	0.000213	0.00157	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Doxorubicin—kidney cancer	0.000211	0.00156	CcSEcCtD
Fidaxomicin—Dry mouth—Capecitabine—kidney cancer	0.000211	0.00156	CcSEcCtD
Fidaxomicin—Nausea—Dactinomycin—kidney cancer	0.000211	0.00156	CcSEcCtD
Fidaxomicin—Dizziness—Vincristine—kidney cancer	0.00021	0.00155	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000206	0.00152	CcSEcCtD
Fidaxomicin—Nervous system disorder—Capecitabine—kidney cancer	0.000203	0.0015	CcSEcCtD
Fidaxomicin—Vomiting—Vincristine—kidney cancer	0.000202	0.00149	CcSEcCtD
Fidaxomicin—Skin disorder—Capecitabine—kidney cancer	0.000201	0.00148	CcSEcCtD
Fidaxomicin—Rash—Vincristine—kidney cancer	0.0002	0.00147	CcSEcCtD
Fidaxomicin—Dermatitis—Vincristine—kidney cancer	0.0002	0.00147	CcSEcCtD
Fidaxomicin—Abdominal pain—Paclitaxel—kidney cancer	0.000199	0.00147	CcSEcCtD
Fidaxomicin—Headache—Vincristine—kidney cancer	0.000199	0.00147	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000198	0.00146	CcSEcCtD
Fidaxomicin—Vomiting—Gemcitabine—kidney cancer	0.000191	0.00141	CcSEcCtD
Fidaxomicin—Rash—Gemcitabine—kidney cancer	0.00019	0.0014	CcSEcCtD
Fidaxomicin—Dermatitis—Gemcitabine—kidney cancer	0.00019	0.0014	CcSEcCtD
Fidaxomicin—Headache—Gemcitabine—kidney cancer	0.000188	0.00139	CcSEcCtD
Fidaxomicin—Nausea—Vincristine—kidney cancer	0.000188	0.00139	CcSEcCtD
Fidaxomicin—Hypersensitivity—Paclitaxel—kidney cancer	0.000186	0.00137	CcSEcCtD
Fidaxomicin—Dyspnoea—Capecitabine—kidney cancer	0.000184	0.00136	CcSEcCtD
Fidaxomicin—Dyspepsia—Capecitabine—kidney cancer	0.000182	0.00134	CcSEcCtD
Fidaxomicin—Decreased appetite—Capecitabine—kidney cancer	0.00018	0.00133	CcSEcCtD
Fidaxomicin—Nausea—Gemcitabine—kidney cancer	0.000179	0.00132	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000178	0.00132	CcSEcCtD
Fidaxomicin—Pruritus—Paclitaxel—kidney cancer	0.000178	0.00131	CcSEcCtD
Fidaxomicin—Constipation—Capecitabine—kidney cancer	0.000177	0.0013	CcSEcCtD
Fidaxomicin—Immune system disorder—Doxorubicin—kidney cancer	0.000169	0.00125	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Capecitabine—kidney cancer	0.000169	0.00125	CcSEcCtD
Fidaxomicin—Dizziness—Paclitaxel—kidney cancer	0.000167	0.00123	CcSEcCtD
Fidaxomicin—Abdominal pain—Capecitabine—kidney cancer	0.000163	0.00121	CcSEcCtD
Fidaxomicin—Malnutrition—Doxorubicin—kidney cancer	0.000163	0.0012	CcSEcCtD
Fidaxomicin—Flatulence—Doxorubicin—kidney cancer	0.000161	0.00119	CcSEcCtD
Fidaxomicin—Vomiting—Paclitaxel—kidney cancer	0.00016	0.00118	CcSEcCtD
Fidaxomicin—Dysgeusia—Doxorubicin—kidney cancer	0.00016	0.00118	CcSEcCtD
Fidaxomicin—Rash—Paclitaxel—kidney cancer	0.000159	0.00117	CcSEcCtD
Fidaxomicin—Dermatitis—Paclitaxel—kidney cancer	0.000159	0.00117	CcSEcCtD
Fidaxomicin—Headache—Paclitaxel—kidney cancer	0.000158	0.00116	CcSEcCtD
Fidaxomicin—Hypersensitivity—Capecitabine—kidney cancer	0.000152	0.00112	CcSEcCtD
Fidaxomicin—Anaemia—Doxorubicin—kidney cancer	0.000151	0.00111	CcSEcCtD
Fidaxomicin—Nausea—Paclitaxel—kidney cancer	0.00015	0.0011	CcSEcCtD
Fidaxomicin—Pruritus—Capecitabine—kidney cancer	0.000146	0.00108	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000138	0.00102	CcSEcCtD
Fidaxomicin—Dizziness—Capecitabine—kidney cancer	0.000137	0.00101	CcSEcCtD
Fidaxomicin—Dry mouth—Doxorubicin—kidney cancer	0.000136	0.001	CcSEcCtD
Fidaxomicin—Vomiting—Capecitabine—kidney cancer	0.000131	0.000969	CcSEcCtD
Fidaxomicin—Nervous system disorder—Doxorubicin—kidney cancer	0.000131	0.000964	CcSEcCtD
Fidaxomicin—Rash—Capecitabine—kidney cancer	0.00013	0.000961	CcSEcCtD
Fidaxomicin—Dermatitis—Capecitabine—kidney cancer	0.00013	0.00096	CcSEcCtD
Fidaxomicin—Headache—Capecitabine—kidney cancer	0.00013	0.000955	CcSEcCtD
Fidaxomicin—Skin disorder—Doxorubicin—kidney cancer	0.000129	0.000955	CcSEcCtD
Fidaxomicin—Nausea—Capecitabine—kidney cancer	0.000123	0.000906	CcSEcCtD
Fidaxomicin—Dyspnoea—Doxorubicin—kidney cancer	0.000119	0.000876	CcSEcCtD
Fidaxomicin—Dyspepsia—Doxorubicin—kidney cancer	0.000117	0.000865	CcSEcCtD
Fidaxomicin—Decreased appetite—Doxorubicin—kidney cancer	0.000116	0.000854	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000115	0.000848	CcSEcCtD
Fidaxomicin—Constipation—Doxorubicin—kidney cancer	0.000114	0.00084	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000109	0.000804	CcSEcCtD
Fidaxomicin—Abdominal pain—Doxorubicin—kidney cancer	0.000105	0.000777	CcSEcCtD
Fidaxomicin—Hypersensitivity—Doxorubicin—kidney cancer	9.82e-05	0.000724	CcSEcCtD
Fidaxomicin—Pruritus—Doxorubicin—kidney cancer	9.43e-05	0.000695	CcSEcCtD
Fidaxomicin—Dizziness—Doxorubicin—kidney cancer	8.81e-05	0.00065	CcSEcCtD
Fidaxomicin—Vomiting—Doxorubicin—kidney cancer	8.47e-05	0.000625	CcSEcCtD
Fidaxomicin—Rash—Doxorubicin—kidney cancer	8.4e-05	0.00062	CcSEcCtD
Fidaxomicin—Dermatitis—Doxorubicin—kidney cancer	8.39e-05	0.000619	CcSEcCtD
Fidaxomicin—Headache—Doxorubicin—kidney cancer	8.35e-05	0.000616	CcSEcCtD
Fidaxomicin—Nausea—Doxorubicin—kidney cancer	7.91e-05	0.000584	CcSEcCtD
